State whether the PDC was analysed as a dichotomous or continuous variable.

If the PDC was dichotomized, provide a rationale for selecting this threshold.

Consider conducting a sensitivity analysis with PDC analysed as a continuous variable, or dichotomized at an alternative cut-off informed from the data, literature or other method.

Define the eligibility criteria for assessing the PDC, e.g. minimum number of scripts required to be filled within a period.

Define the numerator and denominator for the PDC, e.g. The PDC was defined as the total number of days with at least 1 medication available (numerator) in the 1-year period following hospital discharge (denominator).

State whether the PDC was assessed among individuals surviving the entire measurement period or whether the PDC was measured until the date of death for those who died during the observation period.

State whether analyses were limited to new users or how presupply was handled if previous users of medication were included.

State whether information on in-hospital medication dispensing was available.

If unavailable, describe how periods of time spent in hospital were handled, e.g. periods where an individual was admitted to hospital were excluded from both the PDC numerator and denominator.

State whether dosing information was available in the data or imputed.

If applicable, describe the approach used to impute doses and the validity and/or limitations of this method.

Describe how overlapping supplies due to early refills of the same medication (i.e. stockpiling) were handled, e.g. carry-over was granted for early refills of the same drug.

Describe how overlapping supplies of different medications within the same therapeutic class were handled (i.e. therapeutic switches), e.g. carry-over was not granted for therapeutic switches (e.g. switching from simvastatin to atorvastatin).